We are pioneers of the CRISPR technology and at the forefront of what’s next. We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease. Aiming to treat sickle cell disease and β-thalassemia with gene-edited blood stem cells.

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.

At CRISPR Therapeutics, our aim is to find cures for people suffering from serious diseases through transformative gene-based medicines. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy.

Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing.

Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of solid tumors and hematological malignancies that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

Dec 9, 2024 · The Investor Relations website contains information about CRISPR Therapeutics's business for stockholders, potential investors, and financial analysts.

3 days ago · CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

Jan 13, 2025 · CRISPR Therapeutics plans to engage with regulatory authorities to align on the path forward for CTX112 in B-cell malignancies, with an update expected in mid-2025. Preliminary safety, pharmacokinetic, and pharmacodynamic data in oncology highlight the potential of CTX112 in autoimmune indications.

Get the latest Crispr Therapeutics AG (CRSP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

4 days ago · Get a real-time CRISPR Therapeutics AG (CRSP) stock price quote with breaking news, financials, statistics, charts and more.